As a leader in our field, The Teewinot Group is making headlines through our cutting-edge approach to cannabinoid based therapies. Learn more about how we plan to further our mission to address unmet medical needs across the globe through some of our latest press releases and company announcements.

Teewinot Life Sciences In the News

May 22, 2017 Teewinot Life Sciences Corporation Announces New Cannabis Genome Research Program

May 1, 2017 Teewinot Life Sciences Corporation, a Global Leader in Pharmaceutical Cannabinoid Production, Secures $12.3 Million Series B Round

March 20, 2017 Teewinot Life Sciences and Noramco sign letter of intent to produce cannabinoids with CannSynthesis™ biocatalysis technology

March 7, 2017 Teewinot Life Sciences Corporation’s Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids

March 7, 2017 Teewinot Life Sciences Corporation in in-PharmaTechnologist.com, “Nemus hires Catalent to formulate second chemo-induced nausea drug”

February 22, 2017 Teewinot Life Sciences in CBInsights, “Grapeless Wine And Cowless Milk: 60+ Synthetic Biology Startups In A Market Map”

February 16, 2017 Teewinot Life Sciences in Outsourcing-Pharma, “Teewinot ups cannabinoid production capabilities”

February 14, 2017 Teewinot Life Sciences in PRN, “Teewinot Life Sciences Corporation Announces Breakthrough Commercial Production of the Cannabinoid Varin Series”

February 8, 2017 CEO, Jeffrey Korentur, quoted in in-Pharma, “Pot luck? Medical marijuana’s ‘questionable quality’ no threat to pharma R&D”

January 5, 2017 Patented biosynthesis produces ‘authentic, standardized cannabinoids’ for pharma

January 3, 2017 Teewinot Life Sciences’ Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures a New U.S. Patent for Biosynthesis of Cannabinoids

December 20, 2016 Teewinot Life Sciences CEO, Jeffrey Korentur, quoted in SAT Press Releases, “Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules”

December 18, 2016 Teewinot Life Sciences CEO, Jeffrey Korentur, quoted in Indie Sources, “How Medical Marijuana May Be Moving More Toward Actual Medicine”

December 6, 2016 Teewinot Life Sciences Press Release, “Teewinot Life Sciences’ Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures a New U.S. Patent Covering an Apparatus for Biosynthetic Production of Authentic THCA, CBDA and CBCA Cannabinoids”

November 28, 2016 Teewinot Life Sciences President, Robert Hunt, interviewed in Health Business Blog, “Recreational marijuana is becoming legal. How will the laws be implemented?”

November 25, 2016 Teewinot Life Sciences President, Robert Hunt, discusses the cannabinoid market in Scrip Pharma Intelligence | informa, “Cannabinoid Market Snapshot: GW’s Epilepsy Success Bodes Well”

November 16, 2016 Teewinot Life Sciences CEO, Jeffrey Korentur, interviewed in Pharmaceutical Processing, “Cannabinoid-Based Therapies Find a Home in the Pharma Industry”

November 9, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in Forbes, “More States Legalize Marijuana, But Will President Trump Allow It?”

November 8, 2016 Teewinot Life Sciences President, Robert Hunt, quoted on Fox Business, “Marijuana Vote is Big Money This Election”

November 7, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in The Street, “Nasdaq Cannabis Stocks Spike in Volume Ahead of Election for Recreational and Medical Use”

November 7, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in Forbes discussing “Could California’s Marijuana Law Affect The Entire Country?”

November 5, 2016 Teewinot Life Sciences mentioned in Wired article, “Want Your Marijuana Startup to Succeed? Study Patent Law”, for its patents

November 3, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in volteface discussing November’s legalization’s watershed moment

November 1, 2016 Teewinot Life Sciences CEO, Jeffrey Korentur, quoted in Playboy article, “Can Medical and Recreational Weed Coexist?”

October 19, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in Inc., “New Gallup Survey Finds 60 Percent of Adults Support Legal Marijuana Use”

October 18, 2016 Teewinot Life Sciences to present at the prestigious BIO Investor Forum in San Francisco

October 17, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in Forbes discussing Marijuana On The Ballot: State By State Opportunities For Entrepreneurs

October 6, 2016 Teewinot Life Sciences President, Robert Hunt, to present and moderate at the Global Alpha Forum in Stamford, CT

September 15, 2016 Teewinot Life Sciences President, Robert Hunt, is interviewed by WHCU radio in Ithica, NY

September 12, 2016 Dr. Richard Peet, Executive Vice President and Chief Intellectual Property Counsel at Teewinot Life Sciences Corporation presented a seminar at the Cann10 Conference in Tel Aviv Israel entitled “Biosynthesis of Cannabinoids.” Dr. Peet presented a seminar on Teewinot’s disruptive and patent protected processes for manufacture of pure, pharmaceutical grade cannabinoids, cannabinoid prodrugs and cannabinoid analogs.

August 15, 2016 Teewinot Life Sciences President, Robert Hunt, interviewed on the CBS Radio show All Business with Jeffrey Hayzlett

August 11, 2016 Teewinot Life Sciences President, Robert Hunt, quoted in MarketWatch discussing the DEA announcement related to cannabis and cannabinoids

August 2, 2016 Teewinot Life Sciences discussed in a story in Privcap, a global authority on the Private Equity industry

July 19, 2016 Teewinot Life Sciences Secures First U.S. Patent Covering An Apparatus For The Biosynthetic Production Of Authentic THCA, CBDA And CBCA Cannabinoids

June 22, 2016 Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard

June 16, 2016 Tuatara Capital Leadership Interviewed by The Street at the Cannabis World Congress

June 10, 2016 Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.

June 7, 2016 Teewinot Life Sciences Secures First U.S. Patent Covering a Commercial Process for Biosynthetic Production of authentic THCA, CBDA and CBCA Cannabinoids

March 8, 2016 Global Leader In Pharmaceutical Cannabinoid Production Secures $7 Million With Tuatara Capital Leading The Series A Round

March 4, 2016 Teewinot Life Sciences President, Robert Hunt, discussing the how true pharmaceutical based cannabinoid based medicines will be replacing medical cannabis as we know it today (Use password: 420)

Media Relations Contact

Contact: Drew White
Email: drew@nisonco.com
Number: 631-520-1434